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Abstract
Background: Enterovirus 71 (EV71) is a major causative agent of hand-foot-mouth disease (HFMD) and also causes
severe neurological complications, leading to fatality in young children. However, no effective therapy is currently
available for the treatment of this infection.
Methods: We identified small-molecule inhibitors of EV71 from a screen of 968 Food and Drug Administration
(FDA)-approved drugs, with which clinical application for EV71-associated diseases would be more feasible, using EV71
subgenomic replicon system. Primary hits were extensively evaluated for their antiviral activities in EV71-infected cells.
Results: We identified micafungin, an echinocandin antifungal drug, as a novel inhibitor of EV71. Micafungin potently
inhibits the proliferation of EV71 as well as the replication of EV71 replicon in cells with a low micromolar IC50 (~5 μM).
The strong antiviral effect of micafungin on EV71 replicon and the result from time-of-addition experiment demonstrated
a targeting of micafungin on virion-independent intracellular process(es) during EV71 infection. Moreover, an extensive
analysis excluded the involvement of 2C and 3A proteins, IRES-dependent translation, and also that of polyprotein
processing in the antiviral effect of micafungin.
Conclusions: Our research revealed a new indication of micafungin as an effective inhibitor of EV71, which is the first
case reporting antiviral activity of micafungin, an antifungal drug.
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Background
Enterovirus 71 (EV71) is one of the major etiological
agent of hand-foot-mouth disease and also causes severe
neurological symptoms, such as aseptic meningitis, en-
cephalitis and acute flaccid paralysis, which can lead to
even death [1–4]. Since its first discovery in 1969, EV71
outbreak has occurred frequently in the Asia-Pacific re-
gion and caused hundreds of annual deaths. Despite its
enormous threat to public health, currently no effective
vaccines or therapeutic drugs are yet available.
EV71 is a member of human enterovirus A (HEV-A)
species under genus Enterovirus in the Picornaviridae
family [5]. EV71 is a small and non-enveloped virus
with a positive-sense single-stranded RNA genome of
7500–8000 nucleotides that is composed of a long open
reading frame (ORF) flanked by 5’ and 3’nontranslated
regions (NTR) [2, 6]. First, virus particle attaches and
enters into host cells via specific receptors, and then
the viral RNA genome is released into the cytoplasm.
The viral RNA is used as mRNA for the initiation of
translation at the internal ribosomal entry site (IRES) in
the 5’ NTR, producing a large polyprotein. The viral
polyprotein is further cleaved into individual viral pro-
teins (VP4, VP2, VP3, VP1, 2Apro, 2B, 3A, 3B, 3Cpro,
and 3Dpol) by two viral proteases 2Apro and 3Cpro.
Negative-sense RNA genomes are also generated
mainly by the action of 3Dpol and serve as templates for
the production of positive-sense RNA genomes [6].
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Amplified positive-sense RNA genomes are packaged
by structural proteins (VP1, VP2, VP3, and VP4) to pro-
duce infectious viral particles and then released from
the host cell.
Effective antiviral drugs for the treatment of various
diseases associated with enteroviral infection have been
enthusiastically explored. Currently, many synthetic com-
pounds (Gemcitabine [7], Pleconaril [8, 9], CsA [10],
BPROZ [11], GPP3-1 [12], LVLQTM [13], Enviroxime
[14], rupintrivir [15], DTrip-22 [16], and aurintricar-
boxylic acid [17]) and natural products (lycorine [3],
raoulic acid [18], chrysin [19], and ginsenosides [20, 21])
have been reported to have inhibitory activities against
part of or broad range of enteroviruses. However, none
of them has been demonstrated to be sufficiently effect-
ive at the clinical level. Undesirable side effects in vivo
are another limiting factor for the therapeutic applica-
tion of those compounds. Therefore, the development
of new anti-enteroviral drug candidates are urgently
required before the enteroviruses cause more severe
health problems in human society. In this regard, we
chose FDA-approved drugs with proven clinical safety,
with which new clinical application for EV71-associated
diseases would be more favorable, for screen of anti-
EV71 chemicals.
Here, we identified micafungin as an effective inhibitor
of EV71 from a screen of 968 FDA-approved drugs.
Micafungin potently inhibited the proliferation of EV71
in LLC-MK2 Derivative cells and moderately inhibited
that of Coxsackievirus B3 (CVB3) in HeLa cells. More-
over, micafungin showed a strong inhibitory effect on
the replication of EV71 replicon in Vero cells, indicating
its effect on intracellular process(es) that are independent
of the virus particle. As for the mode of action, further
analysis ruled out the involvement of some of intracellular
process(es), such as polyprotein processing by 3Cpro,
IRES-dependent translation, and 2C and 3A proteins,
in the antiviral action of micafungin.
Methods
Cells, viruses, and chemicals
Vero, HeLa, 293 T, LLC-MK2 Derivative, and H1HeLa
cells were used as described previously [7]. EV71 (strain
BrCr) (ATCC VR-1775), EV71 (strain H) (ATCC VR-
1432) were purchased from ATCC, and EV71 (strain
1095) was kindly provided by Yorihiro Nishimura [22].
Those were expanded in LLC-MK2 Derivative cells.
CVB3 and Human rhinoviruses were used as previously
described [7]. FDA-approved drug library version 2 was
purchased from Enzo life science for screen of antiviral
compound. Micafungin (Selleckchem), and Rupintrivir
(Santa Cruz) were purchased and dissolved in DMSO
for further analysis.
Antibodies
Anti-flag and -β-actin monoclonal antibodies were obtained
from Sigma-Aldrich. EV71 3C antibody (GTX630191) was
purchased from GeneTex. Anti-dsRNA J2 mouse monoclo-
nal antibody was purchased from English & Scientific
Consulting Kft. Secondary antibodies conjugated to
horseradish peroxidase or Alexa Fluor 488 were pur-
chased from Thermo Fisher Scientific and Life Tech-
nologies, respectively.
Replicon assay
Plasmids pRibFluc-EV71 wt and p53CB3-LUC, which
contains the firefly luciferase gene in place of the P1
capsid coding region of EV71 and CVB3 viral genome,
were generously provided by Frank J. M. van Kuppeveld
(Utrecht University, Netherlands). Plasmids pRib-LUC-
CB3/T7-wt [23–25] and pRib-LUC-CB3/T7-(2C-A224V,
I227V, A229V or 3A-H57Y) mutant clones [25, 26], were
also used. Ribomax large-scale RNA production system
(Promega) was used for the synthesis of replicon RNAs
[7]. To perform a screen of 968 FDA-approved drugs
(Selleckchem), Vero cells (3 × 105 cells/well) were trans-
fected with 0.4 μg of the EV71 or CVB3 replicon RNAs
using Lipofectamine 2000 (Invitrogen), split into 96 well
plates (2 × 104 cells/well), and simultaneously treated
with 10 μM of chemicals in 1 % DMSO solution. Eight
hours after treatment of EV71 and CVB3 replicons, cells
were assayed for firefly luciferase activity using One-Glo
Luciferase Assay System (Promega). CellTiter-Glo Lumi-
nescent Cell Viability Assays (Promega) was used for meas-
uring cytotoxicity.
Antiviral activity assay
Antiviral activity of chemicals was tested as previously
described [7]. Mock-infected and DMSO (1 %)-treated
cells were regarded as a 100 % survival and virus-infected
and DMSO (1 %)-treated cells were regarded as a 0 % sur-
vival. The antiviral activity of compounds was calculated
as the percentage of the control.
Cell toxicity assay
MTT assay or CellTiter-Glo Luminescent Cell Viability
Assay Kit (Promega) was used for measuring cell toxicity
as described previously [7]. Cell toxicity was calculated
as the percentage of the control.
Immunofluorescence microscopy
Cells in 96-well plate were infected with EV71 (1 MOI)
and treated with micafungin. At 20 h after infection,
cells were fixed and permeabilized with a 3:1 mixture of
ice-cold methanol-acetone. Infected cells were stained
with anti-dsRNA antibody and anti-mouse secondary
antibody conjugated with Alexa Fluor 488 and followed
by counterstaining with 4′,6-diamidino-2-phenylindole
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(DAPI) (Product # 62248, Thermo Scientific). Operetta
system (Perkin Elmer) was used for capturing images.
Viral infection was quantified using HARMONY soft-
ware in Operetta system. The ratio of infection was cal-
culated as the percentage of the control.
Western blotting and RT-PCR
Virus-infected samples were prepared as described in
immunofluorescence microscopy section. Western blot-
ting was performed as previously described [27]. Twenty
hours after infection, total cell lysates were harvested
and analyzed using anti-3C and -β-actin antibodies. RT-
PCR was performed as previously described [28]. For
RT-PCR of viral RNA, total cellular RNAs were purified
using QIAGEN RNeasy Mini Kit according to manufac-
turer’s manual. Reverse transcription was performed with
random hexamer and SuperScript III reverse transcriptase
(Invitrogen). The region spanning from 3B to 3C of EV71
was amplified with primer csp120 (5’-TTGAACCTTAG
TGGTAAGCCCAC-3’) and csp121 (5’-GTGATTGATCC
CTTCTATGAG-3’) and Accupower PCR premix (Bioneer).
The β-actin mRNAs were also analyzed as a loading
control.
Time-of-addition assay
Micafungin (20 μM) and rupintrivir (4 μM) were added
to LLC-MK2 Derivative cells at indicated time points be-
fore or after EV71 infection. At 20 h post-infection, cells
were fixed and stained with anti-dsRNA antibody and
AF488-conjugated anti-mouse secondary antibody. Nuclei
were counterstained with DAPI. The quantification of
viral infection was done as described in immunofluores-
cence microscopy section. Viral infection was calculated
as the percentage of the control.
IRES assay
Dual luciferase reporter plasmids pR/EV71(strain BrCr)/
F-PEST and pR/CVB3/F-PEST were exploited and IRES
assay was performed as previously described [7].
3C protease assay
293 T cells were transfected with pcDNA3-flag-3CD [7]
using X-tremeGENE DNA Transfection Reagent (Roche),
maintained for 15 h, and treated with 10 μM of micafun-
gin for another 9 h before being subjected to Western
blotting with anti-flag antibody.
Results
Screening of anti-EV71 compounds from FDA-approved
drugs
Many compounds have been reported to have anti-EV71
activity in vitro, but their clinical potential needs to be ex-
tensively evaluated. To date no compound has been proved
to be safe and effective in clinical setting. Therefore, we
sought to identify new drug candidate(s) from FDA-
approved drugs, with which clinical application for
EV71-associated diseases would be more favorable,
using EV71 subgenomic replicon system. This replicon
system contains a firefly luciferase gene in place of the
P1 structural genes (VP4-VP1), which allows easy and
quantitative measurements of intracellular viral replica-
tion (Fig. 1a) [23, 24]. According to the preliminary exper-
iments, luciferase activity from Vero cells transfected with
in vitro-transcribed EV71-replicon RNAs increased in a
time-dependent manner and reached a maximum at 10 h
after transfection (Additional file 1: Figure S1). Therefore,
we chose to screen the compounds for antiviral activity by
applying them to the cells for 8 h. Primary screening of
968 FDA-approved drugs (10 μM) in Vero cells trans-
fected with EV71 replicon RNAs identified 21 compounds
that significantly decreased the luciferase activity (more
than 60 % reduction compared with DMSO-treated
control; Fig. 1b).
Next, to examine whether primary hits inhibit the
proliferation of intact EV71 in cells, EV71 (BrCr)-infected
LLC-MK2 Derivative cells were treated with 2 and 10 μM
concentrations of the 21 identified compounds for 96 h
and then analyzed by MTT assay, which is prevalently
used for quantitative measurement of cell viability. In this
assay, EV71 infection causes a cytopathic effect (CPE) on
the LLC-MK2 Derivative cells, reducing the cell viability
by almost 100 %, and any compound with antiviral activity
can cause a relative increase in the cell viability. Among
21 primary hits tested, the treatment with micafungin
most highly increased the cell viability by more than 60 %
compared with the DMSO-treated control (Fig. 1c). In the
same condition, rupintrivir, a potent 3C inhibitor, showed
strong antiviral activity as previously reported [15]. Gem-
citabine, recently identified as an anti-enteroviral com-
pound [7], also showed a moderate anti-EV71 activity.
Intriguingly, micafungin is a well-known antifungal drug
and has never been reported to have any antiviral activity.
Thus, we decided to further investigate its antiviral activity
(Fig. 1d).
Micafungin potently inhibits the proliferation of EV71 in
mammalian cells
To examine how strongly micafungin inhibits the replica-
tion of EV71 in cells, Vero cells were transfected with in
vitro-transcribed EV71-replicon RNAs, immediately
treated with a various concentrations of micafungin for
8 h, and then assayed for luciferase activity. Micafungin
had IC50 of ~5-8 μM for replication of EV71 replicons
(Fig. 2a). In the same condition, it had little cytotoxic ef-
fect in Vero cells, which was assessed using CellTiter-Glo
reagent (Fig. 2b). Similar inhibitory effects were also ob-
served in Vero cells transfected with CVB3-replicon RNAs
(Additional file 2: Figure S2A). Low cytotoxicity of
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micafungin in Vero cells was also confirmed in an experi-
ment with a longer treatment lasting 24 h (Additional file 3:
Figure S3A) and 48 h (Additional file 3: Figure S3B).
The antiviral effect of micafungin was further analyzed
in EV71-infected LLC-MK2 Derivative cells. Cells were
infected with EV71 (strain BrCr) (hereafter referred to as
EV71), simultaneously treated with a broad range of
concentrations of micafungin for 96 h, and then ana-
lyzed by MTT assay. Micafungin exhibited an obvious
dose-dependent antiviral activity, with an estimated EC50
of ~5 μM (Fig. 3a), which is quite similar to that obtained
from replicon assay (Fig. 2a). Apart from this obvious
antiviral activity, there was a slight decrease in cell via-
bility (Fig. 3b) and even in antiviral activity (Fig. 3a) at
50 μM, indicating the possible cytotoxicity. Given that
micafungin had little cytotoxic effect in Vero cells
treated for 24 or 48 h (Additional file 3: Figure S3),
micafungin might have a mild cytotoxicity, particularly
at a higher concentration and longer treatment condition.
Similar antiviral activity was also shown in LLC-MK2 De-
rivative cells infected with EV71 (strain H isolated from
Chinese patient) or EV71 (strain 1095) genotype C2, even
though maximal efficacy was lower than that for EV71
(strain BrCr) (Additional file 4: Figure S4).
To further confirm the antiviral activity of micafungin in
EV71-infected cells, viral proteins and RNAs were analyzed.
EV71-infected LLC-MK2 Derivative cells were treated with
a broad range of concentrations of micafungin for 20 h,
Fig. 2 Micafungin potently inhibits the replication of the EV71 replicon. a Vero cells were transfected with in vitro-transcribed EV71-replicon RNAs,
simultaneously treated with the indicated concentrations of micafungin for 8 h, and then assayed for firefly luciferase activity. The luciferase activity of
DMSO-treated cells was considered to be 100 %. b In the same condition, another set of EV71 replicon-transfected cells was assayed for cell viability
using CellTiter-Glo reagent. The activity of DMSO-treated cells was considered to be 100 %
Fig. 1 Identification of micafungin as an anti-EV71 inhibitor from a screen of the FDA-approved drug library. a Schematic diagram of DNA encoding the
EV71 replicon. b Vero cells were transfected with in vitro-transcribed EV71-replicon RNAs, immediately treated with 968 FDA-approved drugs (10 μM) for
8 h, and then assayed for firefly luciferase activity. Rupintrivir (10 μM) was used as a positive control. The luciferase activities from cells treated with 21
primary hits including micafungin were presented in graph. The luciferase activity from DMSO-treated cells was considered to be 100 %. c The antiviral
activities of the primary hits were further evaluated in EV71-infected LLC-MK2 Derivative cells. The LLC-MK2 Derivative cells were infected with
EV71 (100 CCID50), simultaneously treated with the 21 primary hits (2 and 10 μM) for 96 h, and then cell viabilities were analyzed by using
MTT assay. Rupintrivir (2 and 10 μM) was used as a positive control. The viability of DMSO-treated cells was considered to be 0 %, and that of
uninfected cells was considered to be 100 %. d The chemical structure of micafungin
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and then the total cell extracts and RNAs were pre-
pared and analyzed by Western blot with anti-3C anti-
body and RT-PCR with primers corresponding to the
3B-3C regions, respectively. The amount of EV71 3C
protein decreased by the treatment with micafungin in a
dose-dependent manner and is hardly detected at 10 μM
(Fig. 3c), which is similar to those observed in EV71-in-
fected cells and replicon assays (EC50 = 2–10 μM).
Similar antiviral effects were also shown in the viral
RNA analysis. The amount of EV71 RNAs were dra-
matically reduced by the micafungin treatment with an
estimated EC50 of ~5 μM (Fig. 3d).
Moreover, the strong antiviral activity of micafungin was
further confirmed by another approach, in which EV71-
infected LLC-MK2 Derivative cells were visualized by
staining the dsRNA with an antibody conjugated with a
fluorescent dye, and quantified by counting the stained
cells. EV71-infected cells exhibited a strong fluorescent sig-
nal of the dsRNA and then gradually decreased by a dose-
dependent treatment of micafungin, with an estimated
IC50 of 10 μM (Fig. 3e and Additional file 5: Figure S5).
Collectively, these results clearly demonstrated that mica-
fungin is a strong inhibitor of EV71.
Micafungin has a moderate antiviral activity against other
enteroviruses
In order to examine whether micafungin has an antiviral
effect on a broad spectrum of enteroviruses, we tested
other enteroviruses such as Coxsackievirus group B type
3 (CVB3) and human rhinovirus (HRV), which are also
single-strand, positive-sense enteroviruses that are sig-
nificantly affecting public health. CVB3, one of the most
well-studied enteroviruses and a member of HEV-B, is
one of the main causes of viral meningitis, myocarditis,
and pancreatitis [29, 30]. HRV, the predominant cause of
the common cold, also belongs to the genus Enterovirus
along with EV71 and CVB3 [7]. Micafungin had an
antiviral effect in CVB3-infected HeLa cells, but its ac-
tivity was much weaker than that observed in EV71-in-
fected LLC-MK2 Derivative cells (compare Fig. 3a and
Additional file 6: Figure S6A). Similarly, weak antiviral ac-
tivities of micafungin were also shown in H1HeLa cells
Fig. 3 Micafungin potently inhibits EV71 proliferation in LLC-MK2 Derivative cells. a LLC-MK2 Derivative cells were infected with EV71 (100 CCID50)
and immediately treated with increasing concentrations of micafungin. Four days after treatment, antiviral activity was determined by the reduction of
the cytopathic effect in an MTT assay. Cell viability of DMSO-treated cells was set to 0 % and that of uninfected cells was set 100 %. b Same cells treated
with indicated concentrations of micafungin without EV71 infection were also analyzed for cell viability by using MTT assay. c-e LLC-MK2 Derivative
cells were infected with EV71 (1 MOI) and simultaneously treated with increasing concentrations of micafungin. c Twenty hours post-infection, total cell
extracts were prepared from cells and subjected to Western blot analysis with anti-3C antibody. β-actin was also analyzed as a loading control. d Total
RNAs were prepared from cells in (c) and then subjected to RT-PCR for 3BC region of EV71 viral RNA. β-actin mRNAs were also analyzed as a negative
control. e Twenty hours post-infection, dsRNAs were stained by using specific antibody and visualized by FITC-conjugated secondary antibody (green).
Nuclear DNA was also visualized by DAPI staining (blue)
Kim et al. Virology Journal  (2016) 13:99 Page 5 of 9
infected with three different types of HRV (HRV-14,
HRV-21, and HRV-71) (Additional file 7: Figure S7).
Micafungin affects virion-independent intracellular
processes during EV71 infection
The inhibitory effect of micafungin might affect any step in
the infectious cycle, including attachment, entry, uncoating,
translation, polyprotein processing, replication, assembly,
and release. According to the results in Fig. 2, the inhibitory
effect of the replication of the EV71 replicon by micafungin
provides a clear evidence that micafungin targets intracellu-
lar step(s), which are independent of the virus particle, such
as translation, polyprotein processing, and replication. To
further confirm this observation, micafungin was applied to
the culture medium at various time points during virus in-
fection (−1, 0, 1, 3, 5, 7, 9 and 20 h), and the antiviral effect
of micafungin was assessed by quantifying the infected cells
showing a fluorescent signal of viral dsRNA. The strong
antiviral effect of micafungin was also shown when the
drug was added at 1 h post-infection, and that effect was
nearly as strong as that obtained when the drug was added
prior to or at the time of infection (−1 or 0 h; Fig. 4). Con-
siderable antiviral effect of micafungin sustained until 9 h
post-infection. Overall, time-course effect of micafungin
was quite similar to that of rupintrivir, a well-known 3C in-
hibitor. Consistent with the observation from replicon
assay, these results indicate that micafungin inhibits the
proliferation of EV71 most possibly by targeting any step(s)
after entry in an early viral infection.
In order to further define which step of EV71 infec-
tion, particularly among virion-independent intracellular
processes, is targeted by micafungin, we developed ex-
tensive assays, as reported in our previous study [7], and
examined the involvement of each process in EV71 in-
hibition by micafungin. First, the possibility that mica-
fungin affects translation initiation directed by the IRES
in the 5’ NTR of the EV71 RNA was examined. For this
we used a dual-luciferase reporter system, in which the
expression of the firefly and renilla luciferases is controlled
by EV71 IRES-dependent and cap-dependent translation,
respectively. As a result, micafungin had little effect on fire-
fly luciferase activity in 293 T cells, excluding the involve-
ment of EV71 IRES-dependent translation in the antiviral
effect of micafungin (Fig. 5a). Next, to know whether an
EV71 protease, 3Cpro, can be targeted by micafungin, we
examined the cleavage processing of 3CD. The cleavage
pattern of 3CD precursor protein exogenously overex-
pressed in 293 T cells was not altered at all by the micafun-
gin treatment (Fig. 5b), excluding the association of 3C
protease with the inhibitory effect of micafungin. In con-
trast, treatment with rupintrivir, a 3Cpro inhibitor, obviously
increased the amount of 3CD precursor protein with a re-
ciprocal decrease of 3C protein level (Fig. 5b). In addition,
the involvement of 2C and 3A proteins in the inhibitory ef-
fect of micafungin was also ruled out, because the replica-
tion of EV71 replicons containing well-characterized 2C or
3A drug-resistant mutations were also affected by micafun-
gin to an extent similar to that, to which the replication of
wild-type CVB3 replicon was affected (Fig. 5c). It should
be noted that we took the advantage of 2C or 3A mutant
CVB3 replicons, which were available, for the evaluation of
micafungin because many inhibitors targeting 2C or 3A of
CVB3 also have a similar effect on those of EV71 [26, 31].
Collectively, our mechanistic analyses showed that the
antiviral effect of micafungin is not associated with IRES-
dependent translation, polyprotein processing involving
3Cpro, and 2C and 3A proteins.
Discussion and conclusion
Even though there has been an increasing demand for
antiviral therapy to control EV71 infections, no effective
antiviral drugs of EV71 are currently available. Most of
anti-EV71 inhibitors are only at the preliminary stages of
drug development [6]. Moreover, even rapidly moving
drug candidates such as rupintrivir (a potent 3Cpro in-
hibitor) and pleconaril (a coat protein binder) have been
dropped from further clinical development because of
concerns about viral resistance, side effects, or poor effi-
cacy in patients [32]. Thus, the development of new anti-
viral drugs against EV71 is urgently required before EV71
causes more severe health problems in human beings. To
efficiently achieve this goal, we searched for new antiviral
compounds against EV71 from the FDA-approved drugs,
which would facilitate the clinical application of drug can-
didate for EV71-associated diseases. In the present study,
we identified micafungin, a drug for antifungal therapy, as
an anti-EV71 agent. Extensive analysis in various assay sys-
tems explicitly demonstrated that micafungin is a potent
inhibitor of EV71, which is the first report about its anti-
viral activity.
Fig. 4 Antiviral activity of micafungin depending on the time of
addition. LLC-MK2 Derivative cells were infected with EV71 at 1 MOI and
treated with 20 μM of micafungin or 4 μM rupintrivir at the indicated
times prior to or after virus infection. Twenty hours post-infection,
virus-infected cells were visualized by staining with anti-dsRNA antibody
and percentage of infected cells out of total cells were calculated
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Micafungin is an FDA-approved antifungal drug for
the therapy of diseases associated with Candida infection
mostly. It is a large lipopeptide molecules with a com-
plex aromatic side chain [33], and is classified into echi-
nocandin family which inhibits the synthesis of the cell
wall by targeting β-1,3-D-glucan synthase of fungi [34].
Even though fungi are eukaryotes like human beings, the
cell wall is not shared by either mammalian cells or vi-
ruses [35]. In this regard antiviral effect of micafungin
does not seem to be related with inhibition of β-1,3-D-
glucan synthase. Unfortunately, more biological activities
of micafungin have not been defined yet, thus it is not
easy to explain the precise mechanism of antiviral effect
on EV71. Nevertheless, based on our extensive analysis
we could speculate the possible mode of action that
micafungin probably targets intracellular event during
EV71 infection such as translation, polyprotein processing,
replication, or other such processes rather than virion-
dependent processes such as viral entry and assembly. In
the following studies, the underlying mechanism of anti-
viral effect by micafungin will be further investigated
through the identification of viral mutation(s) conferring
viral resistance to the treatment with micafungin. More-
over, it will be worthy to test the possible antiviral activi-
ties of caspofungin and anidulafungin, which are also
antifungal drugs in echinocandin family [33, 35–37].
In this study, we provide a new function of micafungin,
the drug currently being used for antifungal therapy, as an
effective antiviral inhibitor of life-threatening EV71. Further
validation in virus-infected animal models remains to sug-
gest micafungin as an anti-EV71 drug candidate. Given that
micafungin has been recently reported to show some hep-
atotoxic side-effects in vivo, the effectiveness at a low dose
will be required.
Additional files
Additional file 1: Figure S1. Time-dependent luciferase activity of EV71
replicon in Vero cells. Vero cells were transfected with in vitro transcribed
EV71-replicon RNAs and then firefly luciferase activity was measured at an
interval of two hours. (TIF 80 kb)
Additional file 2: Figure S2. Micafungin inhibits the replication of CVB
replicon. (A) Vero cells were transfected with in vitro transcribed CVB3
replicon RNAs, instantly treated with indicated concentrations of
micafungin for 8 hours and then assayed for firefly luciferase activity.
Luciferase activity of DMSO-treated cells was set to 100 %. (B) At the
same condition another set of CVB3 replicon-transfected cells were
assayed for cell viability by using CellTiter-Glo reagent. Activity of DMSO-
treated cells was set to 100 %. (TIF 100 kb)
Additional file 3: Figure S3. Analysis of the cell toxicity of micafungin.
Vero cells were treated with the indicated concentrations of micafungin
for 24 h or 48 h and then assayed for viability using CellTiter-Glo reagent.
The activity of DMSO-treated cells was considered to be 100 %. (TIF 98
kb)
Fig. 5 Anti-EV71 effect of micafungin is not related with IRES-dependent translation, polyprotein processing, and 2C and 3A. a 293 T cells were
transfected with dual luciferase reporter DNA measuring EV71 IRES-dependent translation and then treated with indicated concentrations of mica-
fungin. Twenty-four hours after compound treatment cells were assayed for firefly and renilla luciferases. Luciferase activities from DMSO-treated
cells were set to 100 %. b 293 T cells were transfected with plasmid expressing flag-EV71(3CD) and then treated with 10 μM of micafungin. Nine
hours after compound treatment total cell extracts were prepared and subjected to Western blot analysis with anti-flag antibody. Rupintrivir
(10 μM) was included as a positive control. c Vero cells were transfected with in vitro transcribed CVB3-wt, CVB3-2C mt, or CVB3-3A mt replicon
RNAs and simultaneously treated with indicated concentrations of micafungin. Eight hours after compound treatment cells were assayed for lucif-
erase activity. Luciferase activities from DMSO-treated cells were set to 100 % for each replicons
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Additional file 4: Figure S4. Antiviral effect of micafingin on EV71
(strains H and 1095). LLC-MK2 Derivative cells were infected with EV71 (H
or 1095) (100 CCID50) and immediately treated with increasing concentra-
tions of micafungin. Four days after treatment, LLC-MK2 Derivative cells
were assayed for viability using MTT reagent. The viability of DMSO-
treated cells was considered to be 100 %. (TIF 93 kb)
Additional file 5: Figure S5. Antiviral effect of micafungin on EV71
infection in LLC-MK2 Derivative cells. LLC-MK2 Derivative cells were in-
fected with EV71 (1 MOI) and simultaneously treated with increasing con-
centrations of micafungin. Twenty hours post-infection, dsRNAs were
stained by using specific antibody and visualized by FITC-conjugated sec-
ondary antibody. Nuclear DNA was also visualized by DAPI staining. Cells
with the fluorescent signal of dsRNAs were counted, and their ratio rela-
tive to the total cells at each concentration was calculated for plotting.
The number of infected DMSO-treated cells was considered to be 100 %.
(TIF 83 kb)
Additional file 6: Figure S6. Antiviral effect of micafungin on CVB3
infection in HeLa cells. (A) HeLa cells were infected with CVB3 (100
CCID50) and simultaneously treated with increasing concentrations of
micafungin. Forty-eight hours after treatment, antiviral activity was deter-
mined by the reduction of the cytopathic effect in an MTT assay. Cell via-
bility of DMSO-treated cells was set to 0 % and that of uninfected cells
was set to 100 %. (B) Same cells treated with indicated concentrations of
micafungin without CVB3 infection were also analyzed for cell viability by
using MTT assay. (TIF 95 kb)
Additional file 7: Figure S7. Antiviral effect of micafungin on three
strains of human rhinoviruses. H1HeLa cells were infected with human
rhinovirus type 14 (A), 21 (B), or 71 (C) (100 CCID50) and immediately
treated with indicated concentrations of micafungin. Three days after
compound treatment antiviral activity was determined by the reduction
of cytopathic effect using MTT assay. Cell viability of DMSO-treated cells
was set to 0 % and that of uninfected cells was set to 100 %. (TIF 100 kb)
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